[有多种疾病的老年人直接口服抗凝剂:什么预防措施?]
Beatriz Alameda1, Sophia Hannou2,3, Julien Derême4
1Centre universitaire de traitement et de réadaptation gériatrique, Service de gériatrie, Département de médecine, Centre hospitalier universitaire vaudois, 1011 Lausanne.
Revue medicale suisse
|October 31, 2024
概括
患有多种健康状况的老年患者面临直接口服抗凝剂 (DOAC) 的更高风险. 通过对DOAC暴露和水平的专业审查,可以在这个人群中识别和管理出血风险.
科学领域:
- 老年学是一门学科.
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 患有多种疾病的老年人容易积累直接口服抗凝剂 (DOAC).
- 诸如功能衰竭,极端年龄/体重,低功能储备和多药性等因素增加了DOACs的出血风险.
研究的目的:
- 评估DOAC暴露,并确定多病症的老年患者的出血风险.
- 为管理DOAC积累和相关风险提出个性化干预措施.
主要方法:
- 药物审查和DOAC暴露的专业评估.
- 由凝血专家对抗Xa活性 (rivaroxaban,apixaban,edoxaban) 的校准测量.
- 作为评估血栓出血风险的工具,D-二聚体测量.
主要成果:
- 通过专家评估和特定的实验室测量,可以确定DOAC积累和相关的出血风险.
- 可以提出个性化干预措施,包括剂量调整或切换DOAC.
结论:
- 参与凝血专家的协作方法对于管理老年多病患者的DOAC治疗至关重要.
- 基于DOAC暴露评估的量身定制的管理策略可以减轻出血风险.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
624
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
624
Factors Affecting Drug Response: Overview
1.9K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
1.9K
Rheumatic Heart Disease IV: Nursing Management
5
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
5
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
477
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
477
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K


